Published in BMC Cancer on October 02, 2006
Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology (2010) 1.75
Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology (2014) 1.46
Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology (2009) 1.31
Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res (2013) 1.21
Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta (2011) 1.17
Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon (2014) 1.17
Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res (2010) 1.17
Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis (2011) 1.14
Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology (2009) 1.12
Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets (2010) 1.11
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol (2008) 0.99
HBx sensitizes cells to oxidative stress-induced apoptosis by accelerating the loss of Mcl-1 protein via caspase-3 cascade. Mol Cancer (2011) 0.98
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol (2008) 0.98
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol (2009) 0.92
Baicalein--an intriguing therapeutic phytochemical in pancreatic cancer. Curr Drug Targets (2012) 0.88
Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma. J Surg Res (2013) 0.87
Antiapoptotic signaling via MCL1 confers resistance to caspase-3-mediated apoptotic cell death in the pregnant human uterine myocyte. Mol Endocrinol (2011) 0.84
Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. J Hum Genet (2013) 0.84
Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers. PLoS One (2014) 0.82
Ulinastatin reduces the resistance of liver cancer cells to epirubicin by inhibiting autophagy. PLoS One (2015) 0.81
New insights in hepatocellular carcinoma: from bench to bedside. Ann Transl Med (2013) 0.80
Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. Invest New Drugs (2009) 0.80
Targeting mcl-1 for radiosensitization of pancreatic cancers. Transl Oncol (2015) 0.80
Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas. Sci Rep (2016) 0.80
Hepatopoietin Cn suppresses apoptosis of human hepatocellular carcinoma cells by up-regulating myeloid cell leukemia-1. World J Gastroenterol (2010) 0.78
MicroRNA-302b Enhances the Sensitivity of Hepatocellular Carcinoma Cell Lines to 5-FU via Targeting Mcl-1 and DPYD. Int J Mol Sci (2015) 0.77
A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase. Cancers (Basel) (2012) 0.76
Reduced ubiquitin-specific protease 9X expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cells. Oncol Lett (2015) 0.76
A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery. Drug Des Devel Ther (2016) 0.75
Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth. Exp Hematol Oncol (2014) 0.75
Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells. J Korean Med Sci (2014) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Hepatocellular carcinoma. Lancet (2003) 22.54
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods (1991) 16.64
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 13.59
Mitochondrial control of cell death. Nat Med (2000) 9.17
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev (2005) 8.95
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 7.97
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol (2004) 5.56
MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A (1993) 5.13
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science (2005) 4.75
Apoptosis in cancer therapy: crossing the threshold. Cell (1994) 4.18
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood (2002) 2.38
Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood (1997) 2.37
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia (2002) 2.17
The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol (1995) 2.10
New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05
Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol (1995) 1.97
Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem (2006) 1.94
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol (2005) 1.77
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther (2005) 1.75
Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem (2005) 1.72
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ (2004) 1.62
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res (2006) 1.53
Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood (2003) 1.53
Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol (2004) 1.43
Mechanisms of human hepatocarcinogenesis. Curr Mol Med (2003) 1.35
Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol (2004) 1.35
Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways. Blood (2000) 1.33
Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology (2004) 1.28
Apoptosis in cancer--implications for therapy. Semin Oncol (2004) 1.27
Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev (1988) 1.25
Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol (2006) 1.20
Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest (2005) 1.19
Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol (2003) 1.16
Disruption of Mcl-1.Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem (2005) 1.11
Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer (1984) 1.11
MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol (2004) 1.10
Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res (2004) 1.04
Distinct roles for extracellular-signal-regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis. Biochem J (2001) 1.04
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep (2006) 1.04
Functional analysis of the human MCL-1 gene. Cell Mol Life Sci (2000) 1.03
Involvement of c-Src kinase in the regulation of TGF-beta1-induced apoptosis. Oncogene (2004) 1.03
The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Cancer (2005) 0.96
Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer (2002) 0.95
Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol (2001) 0.95
Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy (2001) 0.90
Antisense molecules for targeted cancer therapy. Crit Rev Oncol Hematol (2006) 0.88
RNA interference-mediated prevention and therapy for hepatocellular carcinoma. Oncogene (2006) 0.81
Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc (2005) 0.81
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41
Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology (2004) 6.60
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer (2002) 5.87
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology (2003) 5.11
Colorectal cancer. Lancet (2005) 4.90
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology (2007) 4.09
Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science (2002) 3.91
Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest (2003) 3.73
Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl (2006) 3.73
In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol (2006) 3.69
How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J Hepatol (2013) 3.59
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell (2010) 3.25
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest (2005) 2.91
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol (2006) 2.74
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Death receptors in chemotherapy and cancer. Oncogene (2004) 2.64
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg (2012) 2.49
Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology (2012) 2.46
Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol (2005) 2.45
In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. Gastroenterology (2009) 2.33
Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol (2005) 2.28
Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol (2004) 2.22
Death receptor signaling. J Cell Sci (2005) 2.21
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med (2008) 2.18
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol (2009) 2.17
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
Coexistence of Cullen's and Grey Turner's signs in acute pancreatitis. Am J Med (2009) 2.13
Caspases: pharmacological manipulation of cell death. J Clin Invest (2005) 2.10
Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res (2005) 2.05
Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol (2002) 2.04
Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med (2004) 1.95
c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem (2005) 1.93
Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut (2010) 1.92
The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J Exp Med (2006) 1.91
TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J (2005) 1.90
Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol (2010) 1.86
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis (2013) 1.85
TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle (2007) 1.84
IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol (2007) 1.84
Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol (2009) 1.84
Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum (2006) 1.83
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res (2006) 1.82
The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem Biol (2012) 1.82
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med (2006) 1.78
Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology (2010) 1.75
Near-infrared confocal imaging during mini-laparoscopy: a novel rigid endomicroscope with increased imaging plane depth. J Hepatol (2010) 1.74
RNA-Seq Atlas--a reference database for gene expression profiling in normal tissue by next-generation sequencing. Bioinformatics (2012) 1.74
Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol (2007) 1.74
Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc Natl Acad Sci U S A (2002) 1.73
The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J (2006) 1.73
Technology insight: confocal laser endoscopy for in vivo diagnosis of colorectal cancer. Nat Clin Pract Oncol (2007) 1.69
Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity (2013) 1.67
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med (2006) 1.65
Genetics of hepatocellular carcinoma. World J Gastroenterol (2007) 1.64
Confocal laser endomicroscopy. Gastrointest Endosc Clin N Am (2005) 1.64
Medication and Treatment Adherence Following Hospital Discharge. Dtsch Arztebl Int (2016) 1.64
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology (2013) 1.62
High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol (2009) 1.62
Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm Bowel Dis (2008) 1.61
MRI: the new reference standard in quantifying hepatic steatosis? Gut (2011) 1.61
Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol (2006) 1.59
Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy. Gastroenterology (2005) 1.59
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis (2012) 1.58
In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol (2005) 1.58
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58
Dynamics within the CD95 death-inducing signaling complex decide life and death of cells. Mol Syst Biol (2010) 1.57
Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol Cell (2012) 1.57
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut (2011) 1.56
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Liver Dis (2012) 1.55
Pregnancy in primary sclerosing cholangitis. Gut (2011) 1.55
Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell (2012) 1.55
Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J Biol Chem (2007) 1.55
Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med (2004) 1.54
Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO J (2007) 1.53
Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. J Hepatol (2012) 1.52
Endoluminal therapy of GERD with a new endoscopic suturing device. Gastrointest Endosc (2005) 1.50
Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol (2002) 1.50
Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy. Kidney Int (2008) 1.49
Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis (2007) 1.48
Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer (2002) 1.46
Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease. Eur J Gastroenterol Hepatol (2014) 1.46